DNA280 immunoadsorption shows promise for severe lupus nephritis

A network meta-analysis of 24 trials involving 1,442 patients found that DNA280 immunoadsorption combined with conventional therapy showed favorable rankings for reducing disease activity and proteinuria in severe lupus nephritis compared to conventional treatment alone.

• DNA280 immunoadsorption plus standard therapy ranked favorably for improving lupus disease activity scores
• DNA280 combined with plasma exchange significantly reduced 24-hour proteinuria versus standard treatment alone
• Evidence quality was limited by study heterogeneity and reliance on surrogate outcomes

How this compares to prior research

Severe lupus nephritis has historically been difficult to manage with standard immunosuppressive therapy alone, leading researchers to explore adjunctive treatments. Immunoadsorption has been increasingly used to remove pathogenic antibodies from the blood, but comparative evidence across different immunoadsorption column types has been limited. This network meta-analysis represents the first comprehensive comparison of six different immunoadsorption columns for severe lupus nephritis treatment.

Key findings

• DNA280 plus conventional pharmacotherapy showed favorable probability ranking for SLEDAI improvement across 24 randomized controlled trials
• DNA280 plus plasma exchange plus conventional therapy reduced 24-hour proteinuria by 1.8 units versus conventional therapy alone (95% credible interval 0.05–3.5)
• PH-350 plus conventional pharmacotherapy showed favorable probability ranking for serum creatinine improvement

What this means in practice

• Ask your rheumatologist about immunoadsorption options if standard lupus nephritis treatments are not controlling your disease activity
• Consider DNA280-based immunoadsorption combined with plasma exchange if you have severe proteinuria that is not responding to conventional therapy
• Recognize that this evidence is preliminary and higher-quality trials are needed before immunoadsorption becomes standard practice

RESEARCH SNAPSHOT THEPAINSTORY.COM

Download PNG Share: X / Twitter LinkedIn WhatsApp

Frequently asked questions

What is immunoadsorption for lupus nephritis?

Immunoadsorption is an adjunctive treatment that removes harmful antibodies and immune complexes from the blood using specialized columns, used alongside standard immunosuppressive drugs for severe kidney inflammation in lupus patients.

How effective is DNA280 treatment compared to standard therapy?

DNA280 combined with plasma exchange and conventional drugs showed statistically significant advantages for reducing protein in urine, though researchers note the evidence quality is limited and more rigorous trials are needed.

Is immunoadsorption safe for lupus nephritis patients?

Adverse events were reported in 17 of 24 studies, but researchers could not perform comparative safety analyses due to inconsistent reporting methods across trials.

Key terms explained

SLEDAI

Systemic Lupus Erythematosus Disease Activity Index, a scoring system that measures how active lupus disease is in the body.

24-hour proteinuria

The amount of protein leaked into urine over 24 hours, a key marker of kidney damage in lupus nephritis.

Bayesian network meta-analysis

A statistical method that compares multiple treatments simultaneously using probability-based modeling, even when direct head-to-head trials do not exist.

Source: [Efficacy and safety of six immunoadsorption treatments for severe lupus nephritis: a Bayesian network meta-analysis and systematic review.]() · DOI: [doi: 10.3389/fimmu.2026.1661291]()

Originally published on thepainstory.com